Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Menstrual migraine (MM) is a menstrually related disorder (MRD) characterized by several symptoms in common with premenstrual syndrome (PMS). It has been hypothesized that in both MM and PMS hormonal cyclicity could change the balance of neurotransmitters and neuromodulators like monoamine and opioid. In this article we analyze all the data collected by our group on the central opioid tonus and the adrenergic and serotonergic systems in patients affected by menstrual migraine.
Cephalalgia 1995
PMID:Changes of neuroendocrine axes in patients with menstrual migraine. 758 27

Two premenopausal women with a history of menstrually-related migraines and premenstrual syndrome were treated with a combination of vitamin D and elemental calcium for late luteal phase symptoms. Both cited a major reduction in their headache attacks as well as premenstrual symptomatology within 2 months of therapy. These observations suggest that vitamin D and calcium therapy should be considered in the treatment of migraine headaches.
Headache 1994 Oct
PMID:Vitamin D and calcium in menstrual migraine. 800 32

Nefazodone, a new phenylpiperazine antidepressant agent with serotonin type 2 antagonism and serotonin reuptake inhibition, was evaluated in two patient groups to determine its effectiveness in reducing the symptoms of premenstrual syndrome (PMS). The two studied groups were PMS patients with no coexisting major depression or dysthymia (N = 23) and PMS patients with current major depression or dysthymia, termed the premenstrual exacerbation group (N = 24). The two patient groups received open-label nefazodone for 8 weeks, with optional maintenance at the same dose for up to 1 year. The initial dose was 100 mg, titrated to 600 mg/day, on a twice-daily dosing schedule. Symptoms were assessed by the Hamilton Rating Scale for Depression and by Daily Symptom Ratings. Premenstrual symptoms improved significantly from pretreatment baseline values, with similar improvement for the PMS and premenstrual exacerbation groups. Significantly improvement occurred by the end of the first treated cycle (4 weeks of therapy), at an average dose of 245 (range, 100 to 400) mg, and was maintained thereafter. Nefazodone was well tolerated, side effects were often transient, and the most common were nausea and headache. Forty-seven of 54 patients completed 2 months of therapy, with a mean daily nefazodone dose of 319 mg at the 2-month point. A placebo-controlled study should be conducted to confirm and extend these promising preliminary findings.
 ...
PMID:Nefazodone in the treatment of premenstrual syndrome: a preliminary study. 802 14

To investigate the comorbidity of premenstrual syndrome (PMS) and menstrual migraine, the Menstrual Distress Questionnaire (MDQ) was prospectively administered for two consecutive menstrual cycles to 22 patients with menstrual migraine, 12 cases with migraine without aura and 15 patients with PMS. MDQ scores varied throughout the menstrual cycle in each patient group, the wider changes being shown by patients with PMS. Fourteen menstrual migraine patients and 4 migraine without aura patients achieved diagnostic criteria for PMS over two menstrual cycles. In these patients MDQ scores did not differ from PMS sufferers at any stage of the menstrual cycle. The premenstrual increase of each cluster of PMS symptoms was identical in menstrual migraine and PMS subjects with the exception of negative affect. We suggest that PMS symptoms should be taken into account in the IHS diagnostic criteria for menstrual migraine.
Cephalalgia 1993 Dec
PMID:The association of menstrual migraine with the premenstrual syndrome. 831 49

The premenstrual syndrome occurs in the second phase of period and strain, sensitivity, nervousness, anxiety, sleeplessness, headaches, sickness, swollen breasts are the typical symptoms of the syndrome. 143 high school girls have been subjected to the anonymous questionnaire. They were divided into two groups: A--those who showed the symptoms of the premenstrual syndrome, and B--those who did not shown the symptoms. The results of the survey are presented in two sub-scales: fear-condition and fear-feature.
 ...
PMID:[An attempt to apply Spielberg's self-assessment questionnaire in cases of premenstrual syndrome in girls]. 837 20

Variable blood pressure responses, manifesting either as a "white-coat" phenomenon or lability between office visits, confound hypertension management decisions. An attempt was made to determine whether these phenomena are associated with concurrent diagnoses of psychosocial dysfunction, therefore mitigating against antihypertensive medical therapy. Forty-seven patients with such variable blood pressure responses were identified in a rural family practice over a three-year period and compared to randomly selected age- and sex-matched controls for the following concurrent diagnoses: generalized anxiety, psychogenic spastic bladder, panic disorder, depression, alcohol use, chronic headache, fibromyalgia, temporomandibular joint syndrome, irritable bowel syndrome, and premenstrual syndrome. No statistical associations between white-coat hypertension and these diagnoses were demonstrated although a small sample size tempers conclusions. However, chi-square analysis (P < 0.01) of the phenomenon characterized by lability of blood pressure between different office visits demonstrated a statistical association with alcoholic hepatitis in men. White-coat hypertension is a diagnosis that may warrant disassociation from other psychosocial disorders, although further study is indicated. Physicians should remain attuned to the presence of lability of blood pressure in males and consider possible associations with alcoholism.
 ...
PMID:A pilot study of white-coat and labile hypertension: associations with diagnoses of psychosocial dysfunction. 848 44

The diagnosis and pharmacologic management of premenstrual syndrome (PMS) are reviewed. PMS refers to physical or affective symptoms that appear during the latter half of the menstrual cycle, remit during menses, and affect the woman's relationships or ability to function. Pharmacologic treatments proposed for PMS include (1) hormonal treatments that alter the menstrual cycle, (2) hormonal treatments based on specific proposed etiologies, (3) drugs that affect fluid balance, (4) inhibitors or precursors of prostaglandins, (5) nutritional supplements, (6) psychotropic medications, and (7) nonprescription preparations. The menstrual cycle can be manipulated with transdermal estrogen and cyclic oral progesterone, oral contraceptives, danazol, or gonadotropin-releasing hormone agonists with steroid hormone replacement. Psychological symptoms may be treated with fluoxetine, clomipramine, or alprazolam. Patients may be given a diuretic for fluid retention; bromocriptine, tamoxifen, or danazol for mastodynia; and nonprescription analgesics for headaches. PMS can be managed through (1) a symptom-oriented management approach or (2) modification of the menstrual cycle. Pharmacotherapy should be initiated only after simpler measures have failed, and the medication must be chosen carefully, with the severity of the impairment weighed against adverse effects of the treatment.
 ...
PMID:Pharmacologic strategies for managing premenstrual syndrome. 849 Oct 76

The recently developed Tridimensional Personality Questionnaire (TPQ) was used to examine personality correlates in women diagnosed with premenstrual syndrome (PMS). The hypotheses were that the TPQ scores, specifically harm avoidance (HA), would be higher in PMS subjects than in the general population but lower than in depressed populations because major mood disorder is an exclusion from the PMS diagnosis; harm avoidance would have the strongest association with PMS, but other TPQ factors might characterize nondysphoric subgroups in the PMS population. The sample included 157 women who sought medical treatment and met clearly defined criteria for PMS. Two comparison groups of age-matched women with major depression (MDD, N = 20) and premenstrual exacerbation of major depression (MDD + PMS, N = 24) were also evaluated. TPQ scores were significantly higher for PMS subjects on all three dimensions compared with external normative TPQ data. The TPQ dimensions of HA and novelty seeking (NS) were modestly correlated with the premenstrual symptom scores. The HA dimension correlated with premenstrual depression and physical aches; high NS scores correlated with premenstrual food cravings, headache, and mood swings. As hypothesized, the HA scores were significantly higher in the comparison groups diagnosed with major depression; the NS and reward dependence (RD) dimensions did not differ between the PMS and MDD groups. PMS was associated with only modest nonnormative personality correlates, as assessed by the TPQ. Elevations of the HA and NS dimensions were associated with a tendency for the PMS to present with specific symptom patterns: depressive symptoms for the HA factor and food cravings and mood swings for the NS factor. Further research employing other assessment methods is needed to confirm these findings.
 ...
PMID:Personality factors in women with premenstrual syndrome. 855 36

The etiology of PMS has not yet been defined, although there are several theories among which it is reported that there is an increase in prolactine levels involved in it. The purpose of this study was to evaluate a dopamine receptor agonist (lisuride maleate), in the treatment of PMS. 35 patients between 19 and 35 years old were recruited in a prospective study design, with diagnosis of PMS and no other gynecological disorder ruled out clinical and ultrasonographic examination, women with no previous treatment and with no use of hormonal agents, these patients were treated for three months with lisuride maleate, 0.3 mg-day in a three dosage scheme per day, the following symptoms were evaluated: headaches, mastalgia, bloating, edema of lower extremities and myalgia in legs, as well as hormonal parameters before and after treatment with estrogens, progesterone, prolactine, luteinizing hormone (LH), follicle stimulating hormone (FSH) and testosterone, which were prescribed in the luteal phase (day 21). Results obtained were: reduction of all symptoms scores versus pretreatment: Headache from 85.7 to 20%, mastalgia from 91.4 to 25%, bloating from 74.2 to 40%, edema in lower extremities from 85.7 to 30%, myalgia in legs, from 61 to 34%. The hormonal profile only showed changes in FSH, since the basal pretreatment level was found in 18.6 and the post-treatment value was 13.86, progesterone from 2.7 to 4.6 and prolactine from 7.74 to 6.82. We conclude the lisuride maleate is a good option to the PMS treatment, since a significative reduction of symptoms are induced and it is well tolerated.
 ...
PMID:[Treatment of premenstrual tension syndrome (PMS) with lisuride maleate]. 901 40

The premenstrual syndrome is associated with the appearance of distressing somatic, physiological and behavioural symptoms at a certain phase of the menstrual cycle and has not been sufficiently studies with adolescents. The aim of this study is to determine the frequency, severity and period of appearance of the more important somatic and psychological symptoms characteristic of adolescents with PMS. The study includes 186 girls at an age between 16 and 18 years monitored for the period of one year and four months. The most frequently met somatic symptom is headache (39%), the most frequent psychological one--irritability (46%). Sufficient attention is paid to the influence of the menarche and cigarette smoking in adolescents with PMS.
 ...
PMID:[The premenstrual syndrome in adolescents]. 925 55


<< Previous 1 2 3 4 5 6 7 Next >>